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ABSTRACT 
 
 
 
 Human Cytomegalovirus (HCMV) infection can progress into a persistent and life-
threatening disease in infants and immune-compromised individuals, especially when the virus is 
resistant to available antiviral therapies.  The purpose of this project was to study the cellular 
mechanism of activation of antiviral drug MBX 2168, a nucleoside analog that inhibits viral 
DNA replication.  Two proposed pathways (upper and lower) were hypothesized to activate 
MBX 2168.  This project examined both pathways, specifically utilizing de-alkylation inhibitors 
dCF and EHNA to test the involvement of the upper pathway, and in vitro kinase assays to test 
the mono-phosphorylation of synguanol by viral-encoded kinase UL97 (lower pathway).  
Through protein purification, plaque reduction assays, and in vitro assays, the results indicate 
that both pathways theoretically participate in drug activation, but the cell prefers the upper 
pathway.    
 
 3 
TABLE OF CONTENTS 
 
Signature  Page  ……………………………………………………………………….    1 
 
Abstract ………………………………………………………………………………    2 
 
Table  of  Contents  ……………………………………………………………….……    3 
 
Acknowledgements  …………………………………………………………………..    4 
 
Background  …………………………………………………………………………..    5 
 
Project  Purpose  ……………………………………………………………………….  18 
 
Methods  ………………………………………………………………………………  19 
 
Results  ………………………………………………………………………………..  23 
 
Discussion  ……………………………………………………………………………  27 
 
Bibliography  …………………………………………………………………………  30 
 
 4 
ACKNOWLEDGEMENTS 
 
 
 
 First, I would like to thank Microbiotix, Inc. and Terry Bowlin for providing the 
opportunity for me to work in their lab and use their resources to complete this project.  I would 
also like to thank my Major Advisor, Gloria Komazin-Meredith, who was instrumental in 
helping define the project, teach new lab techniques, and provide feedback on the data analysis 
and written report.  Thank you Steve Cardinale for assisting with the HPLC experiments.  I also 
want to thank Donald Coen of Harvard Medical School for donating the baculovirus strain 
expressing glutathione S-transferase (GST)-UL97.  Lastly, I am thankful for Professor Dave 
Adams, who played a critical role in advising this project, by continually providing support and 
feedback and editing the report.  
 
  
 5 
BACKGROUND 
 
The Herpesvirus Family 
The Herpesviridae family consists of an extensive group of double-stranded DNA 
viruses, which includes about 100 known members.  Eight of these viruses are known to infect 
humans, and can be further classified into three subgroups: alpha-, beta-, and gamma- 
herpesviridae.  Their genomes range from 120 to 230 kb, encoding approximately 70 to 200 
genes (Chee et al., 1989).  The alphaherpesviridae group includes herpes simplex virus-1 
(HSV1), herpes simplex virus-2 (HSV2), and varicella zoster virus.  This subgroup is known to 
have a high replication efficiency, broad infectivity, and cause a latent infection in sensory nerve 
ganglia.  In contrast, the betaherpesviridae include human cytomegalovirus (HCMV), human 
herpes virus-6 (HHV6), and human herpes virus-7 (HHV7).  They have longer replication cycles, 
infect a smaller range of mammals, and cause latent infections in the secretory glands, kidneys, 
and reticuloendothelial cells.  The gammaherpesviridae subgroup includes Epstein-Barr virus 
and human herpes virus-8 (HHV8  or  Kaposi’s  sarcoma  virus).  They have a slow replication 
cycle, the most restricted host range, and typically infect lymphoid tissue (Whitley, 1996). 
 
Human Herpesvirus-5 (HHV5/Human Cytomegalovirus/HCMV) Structure 
The human cytomegalovirus (HCMV) structure consists of four main components: the 
envelope, capsid, tegument, and genome (Figure-1).  The envelope consists of a fragile lipid 
bilayer containing glycoproteins which recognize host cell proteoglycans and aid in fusion of the 
virion envelope with the host cell membrane.  The nucleocapsid is icosahedral-shaped consisting 
of 162 capsomers, which surround the double-stranded DNA genome.  The tegument is the space 
 6 
between the capsid and envelope, and contains viral proteins and enzymes that aid in the 
initiation of viral DNA replication (Hunt, 2011). 
 
 
 
 
 
 
 
 
 
 
Figure-1: Structure of Human Cytomegalovirus.  Shown are the main 
components of the HCMV virion, including the envelope, nucleocapsid, 
tegument, and DNA genome (Tomtishen, 2012). 
 
HCMV has the largest genome of all the human herpesviruses (Figure-2).  Its genome is 
about 235 kb long, and includes a high percentage of guanine and cytosine residues compared to 
other herpesviruses.  The genome is organized into two main segments: unique long (UL) and 
unique short (US).  Each of the unique regions is flanked by inverted repeat sequences (Landolfo 
et al., 2003).   
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Figure-2: Map of the HCMV Genome.  The HCMV DNA genome is 
organized into two main regions of unique sequences: the Unique Long 
(UL) region, and the Unique Short (US) region.  The unique regions are 
flanked by two sets of inverted repeats (TRL/IRL and IRS/TRS).  TRL, 
terminal repeat long; IRL, internal repeat long; TRS, terminal repeat 
short; IRS, internal repeat short (Kotenko et al., 2000). 
 
 
HCMV Infection and Replication 
 
HCMV infects and replicates in epithelial cells, endothelial cells, smooth muscle cells, 
mesenchymal cells, hepatocytes, granulocytes, and monocyte-derived macrophages (Landolfo et 
al., 2003).  Viral entrance has evolved to become a quick and efficient process.  The process is 
summarized in Figure-3, and involves the attachment of the virus to cell surface receptors, 
breakup of the viral envelop, entrance of viral DNA into the nucleus, virus gene expression, viral 
assembly, and viral exit from the cell (The Drug Monitor, 2002).   
 
 
 
 
 
 
 
 
Figure-3: Summary of the HCMV Infection and Replication 
Processes.  Shown are the main processes used by HCMV to infect cells, 
resulting in either acute or latent infections (The Drug Monitor, 2002). 
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Surface glycoproteins play a critical role in the recognition and entrance of the virion into 
the cell.  The surface glycoprotein complex gH/gL/UL128-131 and the surface glycoprotein gB 
interact with each other to promote viral fusion and entry into the host cell (Figure-4).  It is 
important to note that the molecular complex of gH/gL/UL128-131 is different than the 
molecular complex gH/gL.  gH/gL/UL128-131 binds to receptors on epithelial cells, while the 
gH/gL complex binds to different receptors on fibroblasts.  Based on current research, it is 
suspected that the binding of these complexes to host receptors activates glycoprotein gB which 
triggers viral fusion into the host cell (Wille et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-4: Structure of the Viral gH/gL/UL128-131 Complex.  The 
straight lines represent the interaction between proteins through disulfide 
bonds, the crossed-lines represent protein interactions through non-
covalent interactions, and the dots represent gH and gL forming a 
specific surface to allow for interaction with UL131 (diagram center).  
Protein gH is transmembrane, and the complex extends into the outer 
environment to interact with the host cell (Ryckman et al., 2008). 
 
After the virus enters the cell, the virion is uncoated and the viral DNA is transported to 
the host cell nucleus, where viral DNA replication is initiated.  Viral DNA replication is 
regulated in an orderly cascade of events through the expression of immediate-early (IE), early 
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(E), and late (L) proteins.  HCMV viral gene expression typically begins one hour post-infection, 
with the transcription of the UL122/123 and auxiliary genes.  These genes encode immediate-
early proteins IE1491aa (IE1-72) and IE2579aa (IE2-86), which are essential for the early stages of 
the viral DNA replication process and control the transcription of a number of viral and cellular 
genes.  For example, IE1-72 initiates the transcription of viral DNA polymerase for replicating 
the viral genome at around 16 hours post-infection, while IE2-86 regulates genes that help 
convert from early-immediate to later stages of viral replication.  IE2-86 also arrests the host cell 
in S-phase, preventing the replication of host DNA (Landolfo et al., 2003).  
The next step in HCMV DNA replication involves  the  transcription  of  β-genes, which 
include UL4, UL44, UL54, and UL112/113.  There are two major subgroups  of  β-genes:  β1  (E  
phase, 4-8  hours  post  infection)  and  β2  (E-L phase, 8-24 hours post infection). The  β-genes are 
responsible for encoding viral replication factors, repair enzymes, and proteins responsible for 
immune invasion.  Viral DNA is usually synthesized at 16 hours post-infection during the early-
protein phase.   UL54 encodes viral DNA polymerase, and UL44 keeps the DNA polymerase on 
the viral DNA template strand.  UL112/113 encodes DNA-binding proteins that are responsible 
for coordinating replication  centers  within  the  host  cell’s  nucleus,  and recruiting the necessary 
proteins and enzymes needed for viral DNA synthesis.  The newly synthesized viral genomes are 
then inverted, cleaved, and processed (Landolfo et al., 2003). 
The final stage of virus replication involves maturation and structural development of 
virions.  The expression of late proteins are a critical component to this process, with 75% of the 
HCMV open reading frames containing genes that encode for late proteins involved in the 
maturation of virions.  The late genes are typically expressed 24 hours post infection and include 
γ1  (24-36  hour  post  infection)  and  γ2  (24-48 hours post infection).  The newly synthesized viral 
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DNA leaves the nucleus and enters the cytoplasm in a temporary nuclear capsid.  The DNA loses 
its temporary nuclear membrane, and gains its tegument and capsid.  Lastly, the structure obtains 
it viral envelope by budding into vesicles within the Golgi apparatus, where it is then transported 
by exocytosis out of the cell, beginning 72 hours post infection (Landolfo et al., 2003).   
 
HCMV Symptoms 
HCMV is a worldwide epidemic, causing serious diseases in infants and immune-
compromised individuals.  HCMV is transmitted through bodily fluids (blood, mucous, semen, 
organ transplants, etc.) or placental transfer.  Between 40 and 100% of the worldwide population 
carry the antibody against HCMV in their blood, indicating infection at some point in their 
lifetime.  Over 90% of the US population has the HCMV antibody by the age of 80 years old.  A 
majority of immune-competent individuals do not experience clinical symptoms, however, about 
10% of HCMV cases in immune-competent patients result in mononucleosis (Public Health 
Agency of Canada, 2011). 
HCMV can be life-threatening in infants infected congenitally.  About 0.2 to 2.4% of 
newborns are infected with HCMV, and of this percentage, 10 to 15% experience severe 
symptoms at birth (Public Health Agency of Canada, 2011; Biron, 2006).  Symptoms of infected 
newborns include low birth weight, jaundice, hepatosplenomegaly, petechiae, hepatits, 
myocarditis, pneumonitis, anemia, CNS abnormalities (seizures, encephalitis, etc.), retinitis, and 
chorioretinitis (Public Health Agency of Canada, 2011; Landolfo et al., 2003).  Approximately 1 
to 20% of newborns infected at birth experience organ failure resulting in death during infancy 
(Landolfo et al., 2003).  Additionally, between 6 to 25% of those congenitally infected but 
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asymptomatic in infancy will develop hearing loss later in life (Public Health Agency of Canada, 
2011). 
HCMV can cause life-threatening disease in immune-compromised people, such as those 
receiving an organ transplant or with AIDS (acquired immune-deficiency syndrome).  HCMV is 
the most frequent fatal viral infection in patients receiving an organ or hematopoietic stem cell 
transplant.  Organ recipients who are HCMV sero-negative but receive an organ transplant from 
a donor who is sero-positive are at greatest risk (Biron, 2006; Landolfo et al., 2003).  Common 
symptoms of HCMV-infected donor recipients include fever, muscle and joint pain, fatigue, low 
white blood cell and/or platelet cell count, and hepatitis.  Pneumonitis, which is typically a result 
of HCMV infection during bone marrow transplants, has high mortality rate of 50 to 90% (Public 
Health Agency of Canada, 2011).  Patients with AIDS are also at a high risk of developing 
HCMV infection.  They often present with similar symptoms to that of organ transplant 
recipients, but also experience retinal damage leading to blindness (Biron, 2006).  Table 1 
summarizes the common syndromes for HCMV-infected patients that are immune-compromised 
from either AIDS or from transplants (Landolfo et al., 2003). 
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Table-1: Medical Conditions Associated with HCMV-Infected Immune-Compromised  
Patients.   
 
 
 
 
 
Shown are the common syndromes caused by HCMV infections in AIDS patients, or in 
patients receiving organ transplants or bone marrow transplants (Landolfo et al., 2003).  
 
Nucleoside Analog Inhibition of Viral DNA Synthesis 
Nucleoside analog inhibition is currently the most common method for treating HCMV 
infections.  The synthetically made nucleosides are similar in structure to naturally occurring 
cellular nucleotides, but are modified to result in the termination of DNA synthesis.  The 
synthetic nucleosides enter a cell and are phosphorylated into tri-phosphate nucleotides by viral 
and cellular enzymes.  Typically, a viral kinase will attach the first phosphate group to the 
nucleoside, and human kinases facilitate the addition of the following two phosphate groups.  
After the nucleoside is phosphorylated, the nucleotide analogs are incorporated into the growing 
viral DNA strand, but their incorporation results in termination of viral DNA replication (Clercq, 
2004; Biron, 2006; Deville-Bonne et al., 2010).  DNA strand elongation is halted because the 
nucleoside  analogs  do  not  contain  the  3’  hydroxyl  group,  which  would have allowed for 
additional nucleotide attachment (Appelboom and Flowers, 1983).  
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Ganciclovir Nucleoside Analog 
Ganciclovir (Figure-5A) was the first drug approved for treatment of HCMV, and 
continues to be the primary method of HCMV treatment.  Viral kinase UL97 phosphorylates 
ganciclovir to its monophosphate form, while human kinases continue to phosphorylate it to its 
di- and tri-phosphate forms.  Ganciclovir triphosphate replaces dGTP in the growing viral DNA 
strand stopping DNA synthesis (Clercq, 2004; Biron, 2006). 
 
 
 
 
 
 
 
Figure-5: Structure of Several Anti-Cytomegalovirus Drugs Currently on 
the Market. (Biron, 2006) 
 
Additional HCMV Antiviral Therapies 
Additional HCMV therapies currently on the market include foscarnet, cidofovir, 
valganciclovir, and fomivirsen (Figure-5). Valganciclovir and cidovir are nucleoside analogs 
with a very similar mechanism of action to that of ganciclovir.  They are both phosphorylated to 
their active forms within the cell, and incorporated into the growing viral DNA strand, 
terminating viral DNA replication.  Foscarnet, a pyrophosphonate analogue, interferes with the 
interaction between pyrophosphate and the viral DNA polymerase (encoded by UL54 gene), 
inhibiting the activity of viral DNA polymerase and preventing viral DNA replication.  
Fomivirsen targets the mRNA of the major immediate-early transcriptional unit of HCMV, 
which plays a critical role in viral infection and replication (Clercq, 2004; Biron, 2006).  
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Several anti-viral drugs are currently in clinical development.  Benzimidazole ribosides 
are a major area of HCMV drug development research because they do not target viral DNA 
polymerase but other critical viral enzymes, such as UL97.  For example, Maribavir, a 
benzimidazole riboside, targets the UL97 viral enzyme, thus inhibiting phosphorylation of viral 
proteins that are critical for DNA synthesis and preventing newly synthesized viral DNA from 
budding and leaving the nucleus. Marbivor is currently in Phase II clinical trials.  BAY 38-4766 
and Letermovir are two additional non-nucleoside antiviral HCMV therapies in clinical 
development. These two drugs target the viral terminase complex, specifically kinases UL56 and 
UL89, which are responsible for viral DNA maturation (Biron, 2006; Goldner et al., 2011).  
Figure-6 below shows several different HCMV drugs (either already on the market or in clinical 
development) and each of their targets (Marschall and Stamminger, 2009).  
 
 
 
 
 
 
 
 
 
 
Figure-6: Diagram of Several Anti-HCMV Drugs and Their 
Targets.  Shown is the replication cycle of HCMV relative to a variety 
of HCMV drugs and the proteins they affect.  The drugs include those 
already on the market and those in clinical development (Marschall and 
Stamminger, 2009). 
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Microbiotix, Incorporated 
Microbiotix, Incorporated is a biopharmaceutical company located in Worcester, 
Massachusetts that focuses on the research and development of small molecule anti-infective 
therapies.  Currently, clinical research is being conducted on hepatitis C virus (HCV) and human 
cytomegalovirus (HCMV) drugs.  Cyclopropavir is a methylenecyclopropane nucleoside 
(MCPN) analog against HCMV, human herpesvirus 6, and human herpesvirus 8 that is currently 
in phase 1b of clinical trials at Microbiotix, Inc. (Scott et al., 2011).  This MQP project examined 
another MCPN analog very similar in structure to cyclopropavir, MBX 2168, which was first 
synthesized at Microbiotix and is also a nucleoside analog drug against HCMV infection 
(Komazin-Meredith et al., 2013).  Figure-7 shows the structures of cyclopropavir and MBX 
2168.  Cyclopropavir has an additional hydroxyl group but no alkyl group off of the oxygen 
(Chou et al., 2014). 
 
 
 
 
 
 
 
 
 
Figure-7: Molecular Structures of Drugs MBX 2168 (Panel A) and 
Cyclopropavir (Panel B).  The red boxes show the difference in the 
hydroxyl groups between the two compounds: MBX 2168 has one 
hydroxyl group and cyclopropavir has two.  The blue boxes illustrate 
how MBX 2168 still has its alkyl group while cyclopropavir is de-
alkylated (Chou et al., 2014). 
 
 
Both cyclopropavir and MBX 2168 have similar mechanisms of activation as ganciclovir.  
However, recent studies have shown that MBX 2168 and cyclopropavir are more broad-spectrum 
analogs and are active against several strains of herpes virus.  Additionally, there is limited 
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cross-resistance between ganciclovir and MBX 2168 (Chou et al., 2014).  This MQP project 
further examined the cellular mechanism of activation of MBX 2168, specifically the potential 
role of adenosine deaminase-like protein 1 (ADAL1) and viral kinase UL97 in the de-alkylation 
and phosphorylation, respectively, of MBX 2168. 
MBX 2168 can be mono-phosphorylated and de-alkylated by two pathways, an upper and 
lower pathway (Figure-8).  In the upper pathway, MBX 2168 is first mono-phosphorylated and 
then de-alkylated.  The lower pathway is the reverse in that MBX 2168 is first de-alkylated and 
then mono-phosphorylated.  Previous research, conducted by Gloria Komazin, has confirmed the 
first step in both the upper and lower pathways: viral kinase UL97 mono-phosphorylates MBX 
2168 in the upper pathway, and adenosine deaminase (ADA) de-alkylates MBX 2168 in the 
lower pathway but with low efficiency.  This MQP project examined the second step in both of 
these processes, specifically the potential role of ADAL1 in the de-alkylation of MBX 2168 
monophosphate in the upper pathway, and the ability of viral kinase UL97 to mono-
phosphorylate synguanol in the lower pathway.  After MBX 2168 is mono-phosphorylated and 
de-alkylated, it proceeds through the remainder of the pathway to be tri-phosphorylated by host 
kinases and is then incorporated into the growing viral DNA strand (Komazin-Meredith, 2013). 
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Figure-8: The Proposed Upper and Lower Pathway for MBX 2168 
Activation.  The portion of the pathway within the yellow box was the 
focus of this MQP project.  The upper pathway (solid arrows) involves 
the initial mono-phosphorylation of MBX 2168 by viral kinase UL97 
and then a de-alkylation by ADAL1.  The lower pathway (dotted 
arrows) involves the initial de-alkylation of MBX 2168 to form 
synguanol, followed by the mono-phosphorylation of synguanol by 
UL97.  dCF is an inhibitor of both ADA and ADAL1.  EHNA inhibits 
only ADA (Komazin-Meredith, 2013). 
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PROJECT PURPOSE 
 
 
 Human Cytomegalovirus infects over 90% of the population by the age of 80 years old.  
Of this percentage of the population, infants and immune-compromised individuals are at the 
highest risk for developing life-threatening symptoms from the infection.  The purpose of this 
project was to study the mechanism of activation of anti-viral nucleoside analog, MBX 2168, and 
specifically the role of viral kinase UL97 and adenosine deaminase-like protein 1 (ADAL1) in 
MBX 2168 activation.  As discussed previously, two pathways have been proposed that activate 
MBX 2168.  This project sought to identify which of the two pathways is the major pathway for 
MBX 2168 activation, and to validate the participation of two key intermediate steps in the 
pathways (highlighted in yellow in Figure-8).  The ability of synguanol to be phosphorylated by 
UL97 was tested by in vitro kinase assays, while the ability of mono-phosphorylated MBX 2168 
to be de-alkylated by ADAL1 was tested by using inhibitors dCF and EHNA in cell based 
assays. 
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METHODS 
 
HFF Cell Culture and Maintenance 
Human foreskin fibroblast (HFF) cells (ATCC, catalog number: SCRC-1041)    were grown 
in minimum essential media (MEM) supplemented with Earl’s  salts  and 10% fetal bovine serum 
(FBS) and incubated at 37°C.  After three to four days of incubation, the cells were passaged.  
The media was removed and the cells were washed once with phosphate-buffered saline (PBS).  
The cells were resuspended, and agitated in trypsin-EDTA solution for two minutes.  The trypsin 
was then removed and replaced with MEM media supplemented with Earl’s  salts  and 10% FBS.  
The cells were transferred to a new flask, split by a 1:3 dilution, and given new supplemented 
MEM media. 
 
Plaque Reduction Assay 
HFF cells were plated at a density of 8.5 x 104 cells per well, and allowed to grow 
overnight at 37ºC.  The cells were then infected with HCMV viral strain AD169 (ATCC, catalog 
number: VR-538, Biosafety Level-2) at a concentration of 80 viral PFU/mL, and incubated at 
37ºC for 1 hr.  A set of six MBX 2168 dilutions (100 µM, 20 µM, 4 µM, 0.8 µM, 0.16 µM, and 0 
µM) was then added to the cells, and they were incubated for 9-11 days at 37ºC.  Some of the 
wells also contained 60 µM of either EHNA or dCF inhibitors.  The MBX 2168 plaque reduction 
assays were performed in quadruplicate. 
After 9-11 days of incubation, the wells were stained with crystal violet stain (0.1% 
crystal violet and 20% methanol) for ten minutes, and then were rinsed with water.  The number 
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of plaques per well were counted under a light microscope, and the data was recorded and 
plotted using the GraphPad Prism software. 
 
SF21 Insect Cell Culture 
SF21 insect cells (obtained from Invitrogen, catalog number: B821-01) were originally 
derived from the pupal ovarian tissue of the fall army worm, Spodoptera frugiperda.  SF21 
insect  cells  were  grown  in  Grace’s  insect  media  supplemented  with  10%  FBS  at  27°C.  After 3-4 
days of incubation, the insect cells were passaged.  The media was removed and replaced with 
new  Grace’s  insect  media.   The cells were gently scraped off the flask and transferred to a new 
flask  at  a  1:3  dilution.    New  Grace’s  insect  media  supplemented  with  10%  FBS  was  added  to  
each flask.  
 
UL97 Expression and Purification 
UL97 viral kinase was expressed in the SF21 insect cells and purified in order to perform 
in vitro kinetic assays to assess the ability of UL97 kinase to mono-phosphorylate the substrate 
synguanol.  SF21 insect cells were infected with baculovirus containing UL97 kinase with a 
glutathione S-transferase (GST) tag on the N-terminus (the baculovirus strain expressing 
glutathione S-transferase (GST)-UL97 was donated to Microbiotix, Inc. by Donald Coen of 
Harvard Medical School).  The infected cells were incubated at 27ºC for 72 hours.  The cells and 
media were then harvested and spun in a swinging bucket rotor at 1000 revolutions per minute 
(RPM) for 5 minutes to pellet the cells.  The supernatant was discarded and the cell pellet was 
stored at -80ºC.   
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Lysis buffer (100 mM Tris pH 7.5, 100 mM potassium chloride, 20% glycerol, 5.8 grams 
of sodium chloride, one protease inhibitor, and distilled water) was added to the frozen UL97 
cell pellet.  The UL97 cell solution was lysed in a French pressure cell press, centrifuged, and 
then filtered through a 0.2 µM HT Tuffryn Membrane (Pall Corporation).  The protein solution 
was purified by running it through a GST affinity chromatography column, followed by an anion 
exchange chromatography column.  After each column, a silver stained SDS-PAGE gel was used 
to identify fractions containing purified UL97.  The fractions containing purified UL97 were 
pooled and concentrated using the Pierce Concentrator, PES, 10K MXCO, 0.5mL by Thermo 
Scientific.  The purified and concentrated UL97 was stored at -80ºC for further analysis. 
 
In Vitro Time Course UL97 Assay 
In vitro kinetic assays with purified UL97 protein were performed in duplicate to 
determine the ability of UL97 to phosphorylate synguanol, and to examine the level of affinity of 
UL97 for synguanol.  The time course assay involved incubating 1 mM of synguanol, 3.2 mM of 
ATP, and kinase buffer (50 mM Tris pH 7.5, 50 mM KCl, 10 mM MgCl2, and 1 mM DTT) at 
37qC.  After 20 minutes, 5 ng/µL of purified GST-UL97 kinase was added to the reaction, which 
was then placed back in the 37qC incubator.  At selected times, aliquots were taken and stopped 
with 2% trifluoroacetic acid (TFA).  The formation of synguanol monophosphate was measured 
by UV absorbance (280 nm) on a reverse phase high-performance liquid chromatography 
(HPLC) column.  Solvent A contained 0.1% TFA (Sigma Chemical, St. Louis, MO) in H2O 
(EMD Chemicals Inc., Gibbstown NJ), and solvent B had 0.1% TFA in 100% acetonitrile (EMD 
Chemicals Inc., Gibbstown, NJ).  A Grace Altima protocol (Grace Davison Discovery Sciences, 
Deerfield, IL) was utilized to improve sample (100 µL injections) resolution. A 150-mm by a 
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4.6-mm 5-µm C18 column was used with a gradient of 5% solvent B to 30% solvent B over a 
time period of 25 minutes for synguanol.  Liquid-Chromatography Mass-Spectroscopy (LC/MS) 
(LCQ Fleet) was then used to verify the identity of synguanol monophosphate.  The data 
generated by reverse phase HPLC for the time course and kinetics assays were plotted using 
GraphPad Prism software. 
The kinetics assay involved introducing different concentrations of synguanol (0.25, 0.5, 
1, 1.5, 2 mM) to a mixture of 3.2 mM of ATP, kinase buffer (50 mM Tris pH 7.5, 50 mM KCl, 
10 mM MgCl2, and 1 mM DTT) and 5 ng/µL of UL97 during the linear phase of synguanol 
monophosphate formation (180 minutes) at 37qC.  The reaction was stopped with 2% 
trifluoroacetic acid (TFA), and UL97 kinetics were measured by reverse phase HPLC utilizing 
the same parameters as explained in the time course assay above.  The results were recorded and 
plotted using the GraphPad Prism software. 
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RESULTS 
 
 
HCMV is a worldwide epidemic in which over 90% of the US population will be infected 
at some point their lifetimes.  HCMV infection is particularly life threatening in infants and 
immune-compromised individuals if they carry a HCMV strain that is resistant to available 
antiviral therapies (Public Health Agency of Canada, 2011).  The purpose of this MQP project 
was to examine the role of two proposed upper and lower pathways in activating antiviral drug 
MBX 2168, a nucleoside analog that inhibits DNA replication.  More specifically, this projected 
sought to identify which of the two pathways is the major pathway, and to validate two key 
intermediate steps in the pathways:  1) the ability of viral kinase UL97 to directly phosphorylate 
synguanol, and 2) the ability of ADAL1 to de-alkylate mono-phosphorylated MBX 2168. 
The first part of the project focused on determining whether synguanol is a good substrate 
for viral kinase UL97, which would result in mono-phosphorylation of synguanol and validate 
the minor pathway.  In vitro time course and kinetics assays were performed with purified UL97 
to confirm its role in phosphorylation within the minor pathway.  Figure 9A shows the proposed 
reaction by which UL97 mono-phosphorylates synguanol.  Figure 9B shows the SDS-page gel 
of purified UL97 protein after affinity (column 1) and anion exchange (column 2) column 
chromatography.  A pure protein band at the expected size of 110 kDa was obtained after the 2nd 
column, providing a sufficient amount of kinase to perform several kinase assays.  Panels 9C 
and 9D show the data from the in vitro time course and kinetics assays.  A linear increase in the 
formation of synguanol monophosphate was observed during the first 7 hours of incubation, and 
the product continued to increase from seven to twenty-four hours but at a slower rate.  The 
Michaelis-Menten plot (Panel 9D) yielded a UL97 Michaelis constant (Km) value of 6.4 mM and 
a maximum reaction velocity (Vmax) value of 6.4 pmol/minute.  The increase in the formation of 
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synguanol monophosphate and the low Km value indicate that synguanol is a good substrate for 
viral UL97. 
 
Figure 9:  In Vitro Kinase Assays: Direct Phosphorylation of Synguanol by Viral Kinase UL97.  Panel A 
shows a reaction by which viral kinase UL97 phosphorylates synguanol (minor pathway for drug activation).  Panel 
B shows the SDS-page gel of purified UL97 kinase (110kDa) after GST affinity chromatography (column 1) and 
after anion exchange chromatography (column 2).  Panel C shows the time course assay of the mono-
phosphorylation of synguanol by purified UL97 kinase in vitro.  The concentration of synguanol-PO4 produced was 
determined by comparison to a non-phosphorylated synguanol standard curve (molar absorptivity was treated as 
equal).  Panel D shows a Michaelis-Menten plot yielding a Km of 6.4 mM and a Vmax of 6.5 pmol/min.  This data 
supports the involvement of the minor pathway in MBX 2168 drug activation. 
 
 25 
The second part of the project involved using plaque reduction assays to determine 
whether ADAL1 de-alkylates the monophosphate form of MBX 2168.  In this assay, activation 
of MBX 2168 within the cell results in a decrease in the number of viral infected plaques.  Panel 
10A provides the proposed reaction by which ADAL1 de-alkylates MBX 2168 monophosphate.  
The HCMV viral-infected cells were incubated with MBX 2168 and either ADAL1 inhibitor 
dCF or ADA inhibitor EHNA (previously shown in Figure-8).  Panel 10B provides the data from 
the plaque reduction assays in 3 different conditions: MBX 2168 without inhibitor, MBX 2168 in 
the presence of dCF (which blocks both upper and lower pathways), and MBX 2168 in the 
presence of EHNA (which blocks only the lower pathway).  MBX 2168 with no inhibitor (black 
line) showed substantial plaque reduction over the drug concentration range tested, with an IC50 
value of 0.15 µM (in this case it took only 0.15 µM of MBX 2168 to inhibit 50% of the HCMV 
infection).  MBX 2168 in the presence of EHNA (blue line, blocking only the lower pathway) 
showed an IC50 value of about 0.16 µM, which was not significantly different than without any 
inhibitor.  This data indicates that the lower pathway is not the preferred pathway in this type of 
cell.  Lastly, MBX 2168 in the presence of dCF inhibitor (red line, blocking both upper and 
lower pathways) had significantly more plaques than MBX 2168 with no inhibitor or MBX 2168 
with EHNA, with an IC50 value of 6.92 µM, which was 46-fold higher than MBX with no 
inhibitor, and 42-fold higher that MBX 2168 with EHNA.  The high IC50 value for MBX 2168 in 
the presence of dCF, suggests that these two pathways together represent the main mode of drug 
activation in these cells.  
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Figure 10: Plaque Reduction Assays for HCMV Virus.  Panel A shows the reaction by which ADAL1 de-
alkylates the mono-phosphate form of MBX 2168, which is blocked by ADAL1-inhibitor dCF.  Panel B shows 
HCMV plaque reduction in the presence of increasing concentrations of MBX 2168.  dCF (red) significantly 
reduced MBX 2168 activity (upper pathway), but it remained unchanged in the presence of ADA inhibitor EHNA 
(blue) (lower pathway).  Together the plaque reduction data suggests that ADAL1 (upper pathway) is the  cell’s  
preferred pathway for activating MBX 2168.  
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DISCUSSION 
 
 
Nucleoside analog drugs are a relatively effective form of HCMV therapy, in which they 
are tri-phosphorylated and incorporated into the growing viral DNA strand which results in 
inhibition of viral DNA replication (Deville-Bonne et al., 2010).  Ganciclovir is the primary 
nucleoside analog used to treat HCMV infection (Clercq, 2004; Biron, 2006).  A new analog 
synthesized at Microbiotix, MBX 2168, has a similar mechanism of activation as ganciclovir but 
is a more broad-spectrum analog inhibiting replication of multiple strains of the herpes virus 
(Komazin-Meredith et al., 2013).  Additionally, MBX 2168 also has limited cross-resistance to 
ganciclovir (Chou et al, 2014).  This MQP project focused on two key intermediate steps of 
MBX 2168 activation.  The upper pathway involves the initial mono-phosphorylation of MBX 
2168 followed by its de-alkylation.  The lower pathway is the reverse of the upper pathway, 
where MBX 2168 is first de-alkylated and then mono-phosphorylated (Komazin-Meredith, 
2013).  
Based on the plaque reduction assay data, the upper pathway appears to be the major 
pathway.  MBX 2168 with dCF, which inhibits both the upper and lower pathways (by inhibiting 
ADAL1 in the upper pathway and ADA in the lower pathway) (Komazin-Merideth, 2013) 
showed a significant increase in IC50 (reduced drug activation), indicating that the two pathways 
represent a major mode of drug activation in these cells.  MBX 2168 with ADA inhibitor EHNA 
(which blocks the lower pathway) showed no significant difference from MBX 2168 without any 
inhibitor.  If both pathways were equally utilized, it would be expected that MBX 2168 in the 
presence of EHNA would have an IC50 value between MBX 2168 without inhibitor (0.15 µM) 
and MBX 2168 with dCF (which blocks both pathways, 6.92 µM).  However, MBX 2168 in the 
presence of EHNA had a low IC50 value of about 0.16 mM, statistically indistinguishable from 
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MBX 2168 without inhibitor.  These results suggest that EHNA had no significant effect on 
inhibiting MBX 2168 activation, and that MBX 2168 was fully activated by the upper or major 
pathway.  
The plaque reduction data also validates the involvement of the de-alkylation of mono-
phosphorylated MBX 2168 reaction as an intermediate in MBX 2168 activation.  dCF is known 
to inhibit both ADA and ADAL1 (Faletto et al., 1997).  Therefore, as expected, the results 
showed significantly more plaque formation in the presence of dCF, indicating that dCF is most 
likely inhibiting ADAL1 in the upper pathway.  Further plaque reduction assays need to be 
conducted to confirm the data presented in this report.  Furthermore, it was difficult to purify a 
sufficient amount of ADAL1 protein to run in vitro assays, so further experimentation is needed 
to optimize ADAL1 purification.  Purified ADAL1 could then be used to run in vitro assays to 
confirm the de-alkylation of the mono-phosphate form of MBX 2168 by ADAL1 and determine 
the  protein’s  Km and Vmax values by HPLC and mass spectroscopy. 
With respect to the in vitro kinase assays performed with purified UL97 kinase, the data 
presented in this report (Figure-10) suggests that synguanol is a substrate for UL97, as shown by 
the relatively low Km of 6.4 mM (high enzyme-substrate affinity).  The UL97 Km for synguanol 
has a similar value to previous research conducted at Microbiotix, with UL97 having a Km value 
of 5.3 mM for MBX 2168 and 3.4 mM for MBX 1616 (Komazin-Meredith et al., 2014).  
However, the literature also indicates that the UL97 Km value is even lower for some other 
compounds, such as cyclopropavir (1.75 mM) (Gentry et al., 2010) and resistant strains of 
ganciclovir (ranging from 0.025 to 0.040 mM depending on the mutant strain) (Shannon-Lowe 
and Emery, 2010).  Compared to the affinity of UL97 for other compounds, synguanol appears to 
be a sufficient substrate for UL97.  Additionally, there was a linear increase in the amount of 
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synguanol monophosphate formed when incubated with purified UL97 over a 7 hour time 
period, confirming the second step in the lower pathway: the direct formation of synguanol 
monophosphate from synguanol.  As mentioned above, this experiment was performed in 
duplicate and thus should be repeated to further validate the results presented and discussed in 
this report. 
In conclusion, both the lower and upper pathways were shown in this report to 
theoretically lead to the activation of MBX 2168; however, based on the plaque reduction data, it 
appears the upper pathway predominates in these cells.  Additionally, the results indicate that 
synguanol is a good substrate for UL97 kinase in the lower pathway, so it theoretically can occur 
within these cells, although at a lower rate than the preferred pathway.  Further experimentation 
and analysis is needed to fully understand the mechanism of activation of MBX 2168 within the 
cell and understand its ability to combat HCMV infection. 
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